Education
About Us
Working with TipRanks
Follow Us
Dermata Therapeutics, Inc. (DRMA)
:DRMA
DRMA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $5.00
Previous CloseN/A
Volume28.34K
Average Volume (3M)104.93K
Market Cap
$4.94M
Enterprise Value$647.68M
Total Cash (Recent Filing)$9.72M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.16
Next Earnings
Aug 07, 2025EPS Estimate
-0.29Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding6,378,118
10 Day Avg. Volume93,531
30 Day Avg. Volume104,927
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)-26.10
Price to Sales (P/S)0.00
P/FCF Ratio-165.31
Enterprise Value/Market Cap131.20
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-17.97
Forecast
1Y Price Target
$3.00Price Target Upside289.61% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Dermata Therapeutics News
PremiumCompany Announcements
Dermata Therapeutics Begins Manufacturing for STAR-2 Trial
PremiumCompany Announcements
Dermata Faces Nasdaq Delisting Risk Over Bid Price
PremiumCompany Announcements
Dermata Reports Positive Phase 3 Trial Results
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsXYNGARI demonstrated statistically significant improvements over placebo as early as four weeks into treatment, highlighting its rapid efficacy.
Market OpportunityThe analyst sees significant opportunities for DRMA in the acne, psoriasis, and aesthetic treatment markets due to its unique Spongilla technology.
Product InnovationXYNGARI's once-weekly application could improve patient adherence compared to currently FDA-approved topicals that require daily application.
Bears Say
Financial StrategyDRMA is pre-revenue and is expected to require a capital raise to fund ongoing operations and future trials.
Funding And PartnershipsThe company is pre-revenue and anticipates requiring a capital raise before the second Phase 3 clinical trial.
Share Price TargetBased on expected share dilution from an anticipated capital raise, the 12-month price target is being lowered to $3.00, from $6.00.
Options Prices
Currently, No data available
---
Ownership Overview
22.57% Insiders
0.13%
Mutual Funds
6.44% Other Institutional Investors
70.85% Public Companies and Individual Investors
DRMA FAQ
What was Dermata Therapeutics, Inc.’s price range in the past 12 months?
Dermata Therapeutics, Inc. lowest stock price was $0.66 and its highest was $5.00 in the past 12 months.
What is Dermata Therapeutics, Inc.’s market cap?
Dermata Therapeutics, Inc.’s market cap is $4.94M.
When is Dermata Therapeutics, Inc.’s upcoming earnings report date?
Dermata Therapeutics, Inc.’s upcoming earnings report date is Aug 07, 2025 which is in 54 days.
How were Dermata Therapeutics, Inc.’s earnings last quarter?
Dermata Therapeutics, Inc. released its earnings results on May 14, 2025. The company reported -$0.45 earnings per share for the quarter, the consensus estimate of -$0.45 by $0.
Is Dermata Therapeutics, Inc. overvalued?
According to Wall Street analysts Dermata Therapeutics, Inc.’s price is currently Undervalued.
Does Dermata Therapeutics, Inc. pay dividends?
Dermata Therapeutics, Inc. does not currently pay dividends.
What is Dermata Therapeutics, Inc.’s EPS estimate?
Dermata Therapeutics, Inc.’s EPS estimate is -0.29.
How many shares outstanding does Dermata Therapeutics, Inc. have?
Dermata Therapeutics, Inc. has 6,378,118 shares outstanding.
What happened to Dermata Therapeutics, Inc.’s price movement after its last earnings report?
Dermata Therapeutics, Inc. reported an EPS of -$0.45 in its last earnings report, expectations of -$0.45. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Dermata Therapeutics, Inc.?
Currently, no hedge funds are holding shares in DRMA
Company Description
Dermata Therapeutics, Inc.
Dermata Therapeutics, Inc. (DRMA) is a clinical-stage biotechnology company focused on developing and commercializing innovative pharmaceutical products for the treatment of medical and aesthetic skin conditions. The company operates in the biotechnology and pharmaceuticals sectors, leveraging its unique Spongilla technology platform to address unmet needs in dermatology.
DRMA Stock 12 Month Forecast
Average Price Target
$3.00
▲(289.61%Upside)